M&A
Biocon acquires Eywa Pharma's US plant for $7.7 M
Publicly listed, Bengaluru-headquartered Biocon Ltd, via its US-based wholly-owned step-down subsidiary Biocon Generics Inc, has acquired Eywa Pharma Inc.'s oral solid dosage manufacturing facility, located in Cranbury, NJ (USA), for USD 7.7 million. As part of the acquisition, the existing workforce of the facility will transition to Biocon. The facility has the potential for capacity expansion up to 2 billion tablets/capsules per year.
From the Venture Intelligence PE-VC Deal Database: In Oct 2016, Singapore- and Chennai-headquartered Eywa Pharma (part of the Shriram Group) has raised $30 M from Eight Roads Ventures, Others
Want to receive such news items in your inbox? Click Here to sign up for a trial.
